Join the Pembrolizumab group to help and get support from people like you.
Pembrolizumab News
FDA Approves Merck’s Keytruda (pembrolizumab) Plus Carboplatin and Paclitaxel as Treatment for Adult Patients With Primary Advanced or Recurrent Endometrial Carcinoma
RAHWAY, N.J.--(BUSINESS WIRE) June 17, 2024 – Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved...
Alternative Pembrolizumab Administration Yields Environmental Advantages
THURSDAY, June 13, 2024 – Alternative pembrolizumab administration strategies may have environmental advantages, such as less carbon dioxide emission, according to a study published in the June...
Improvement Seen in Survival With Adjuvant Pembrolizumab in Kidney Cancer
THURSDAY, April 18, 2024 – For patients with clear-cell renal cell carcinoma, adjuvant pembrolizumab is associated with a significant and clinically meaningful improvement in overall survival,...
Adding Vaccine to Immunotherapy for Liver Cancer Shows Promise in Early Trial
TUESDAY, April 9, 2024 – A custom-made anti-tumor vaccine added to standard immunotherapy was twice as likely to shrink liver cancer as when a patient received immunotherapy alone, a new study...
Survival Up With Enfortumab Vedotin + Pembrolizumab in Urothelial Cancer
FRIDAY, March 8, 2024 – For patients with previously untreated locally advanced or metastatic urothelial carcinoma, enfortumab vedotin and pembrolizumab yield significantly better survival than...
Pembrolizumab Improves Event-Free Survival in Early NSCLC
TUESDAY, Feb. 13, 2024 – For patients with early-stage non-small cell lung cancer (NSCLC), event-free survival (EFS) is improved with neoadjuvant pembrolizumab and chemotherapy, according to a study...
Pembrolizumab Shows Survival Benefit for Patients With Renal Cancer
WEDNESDAY, Jan. 31, 2024 – For patients with clear-cell renal cell carcinoma (ccRCC), overall survival (OS) is improved for those receiving pembrolizumab versus placebo at a median follow-up of...
FDA Approves Merck’s Keytruda (pembrolizumab) Plus Chemoradiotherapy as Treatment for Patients With FIGO 2014 Stage III-IVA Cervical Cancer
Keytruda is the first and only anti-PD-1 therapy approved in combination with chemoradiotherapy for these patients Approval marks third FDA-approved indication for Keytruda in cervical cancer and...
Padcev (enfortumab vedotin-ejfv) with Keytruda (pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer
Padcev plus pembrolizumab approved based on groundbreaking EV-302 trial Confirmatory trial found Padcev plus pembrolizumab nearly doubled median overall survival compared to standard of care...
Pembrolizumab + Standard Chemotherapy Beneficial in Mesothelioma
WEDNESDAY, Nov. 15, 2023 – The addition of pembrolizumab to standard platinum-pemetrexed chemotherapy results in significant improvement in overall survival among patients with advanced pleural...
FDA Approves Merck’s Keytruda (pembrolizumab) Plus Gemcitabine and Cisplatin as Treatment for Patients With Locally Advanced Unresectable or Metastatic Biliary Tract Cancer
RAHWAY, N.J.--(BUSINESS WIRE) November 1, 2023 – Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has...
ESMO: Pembrolizumab + Chemo, Trastuzumab Beneficial in Gastroesophageal Cancer
WEDNESDAY, Oct. 25, 2023 – For patients with HER2-positive gastroesophageal junction (GEJ) adenocarcinoma, pembrolizumab improves progression-free survival when combined with chemotherapy and...
FDA Approves Keytruda (pembrolizumab) for Treatment of Patients With Resectable NSCLC in Combination With Chemotherapy as Neoadjuvant Treatment, Then Single Agent as Adjuvant Treatment After Surgery
RAHWAY, N.J.--(BUSINESS WIRE) October 16, 2023 – Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has...
FDA Approves Merck’s Keytruda (pembrolizumab) in Combination With Padcev (enfortumab vedotin-ejfv) for First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer
RAHWAY, N.J.--(BUSINESS WIRE) April 3, 2023 – Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved...
FDA Approves Keytruda (pembrolizumab) as Adjuvant Treatment Following Surgical Resection and Platinum-Based Chemotherapy for Patients With Stage IB (T2a ≥4 Centimeters), II, or IIIA Non-Small Cell Lung Cancer (NSCLC)
Approval based on KEYNOTE-091 trial, which demonstrated a clinically meaningful improvement in disease-free survival with KEYTRUDA in these patients following surgical resection and platinum-based...
Further information
Related condition support groups
Breast Cancer, Colorectal Cancer, Endometrial Cancer, Gastric Cancer, Hepatocellular Carcinoma, Melanoma, Non-Small Cell Lung Cancer, Ovarian Cancer, Renal Cell Carcinoma